jurpsy schreef op 8 juli 2018 08:22:
oa. mogelijke overname in de sector.
Niet onbelangrijk deze week (10 juli) wat er staat te gebeuren met Biocryst en Idera. Vicent Milano is de ex CEO van Viropharma. die weet als geen ander wat er gaande is in de HAE markt. Als Idera deze stap mag zetten van haar aandeelhouders kan dit de rabbit factory eveneens een boost geven.
January 22, 2018.
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases ,
The combination of two companies is expected to capitalize on the collective skills sets, internal expertise and combined assets to create a comprehensive, sustainable rare disease-focused biotechnology leader highlighted by:
? A robust development pipeline, including 4 late stage programs that provide near-term commercial and partnering opportunities:
o BCX7353 – Phase 3 program for the prophylactic treatment of Hereditary Angioedema (HAE) in a capsule formulation with FDA orphan drug designation
o IMO-2125 – Phase 3 program for the treatment of PD1-refractory melanoma in combination with ipilimumab with FDA orphan drug designation
o IMO-8400 – Phase 2 program for dermatomyositis
o BCX7353 – Phase 2 program for the acute treatment of HAE in a liquid formulation
Idera Pharmaceuticals and BioCryst Pharmaceuticals Inc. said Tuesday they have rescheduled, to July 10
, their respective special shareholder meetings to vote on the proposed merger of the two biopharmaceutical companies.
Wie is Vincent Milano?
Chief Executive Officer /Idera.
Mr. Milano joined Idera as Chief Executive Officer in December 2014. Mr. Milano joined ViroPharma in 1996 and served as Vice Mr. Milano most recently served as Chairman, President and Chief Executive Officer of ViroPharma, which was acquired by Shire Pharmaceuticals in January 2 014. Under his stewardship, ViroPharma became a leading developer of innovative therapies for rare diseases, with the approval and commercialization of its lead product, Cinryze, for the treatment of hereditary angioedema in the United States and Europe.
President, Chief Financial Officer and Treasurer from 1997 to 2006 prior to becoming Chief Executive Officer. He was instrumental in building the company, including leading efforts in raising nearly $900 million in capital, as well as acquisitions of Lev Pharmaceuticals
and the drug Vancocin from Eli Lilly. In addition, he played critical roles in business development and investor relations activities for ViroPharma, as well as contributed significantly to establishing the strategic focus of the company. Prior to joining ViroPharma, he served as a senior manager at KPMG LLP, an independent registered public accounting firm.
Mr. Milano currently serves on the Boards of Directors of Spark Therapeutics, Vanda Pharmaceuticals, and VenatoRx. He received his Bachelor of Science degree in accounting from Rider College.